A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,402,972 shares of DYN stock, worth $57.6 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
2,402,972
Previous 3,328,000 27.8%
Holding current value
$57.6 Million
Previous $117 Million 26.51%
% of portfolio
0.16%
Previous 0.22%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$31.94 - $47.04 $29.5 Million - $43.5 Million
-925,028 Reduced 27.8%
2,402,972 $86.3 Million
Q2 2024

Aug 14, 2024

BUY
$23.65 - $35.63 $23.7 Million - $35.7 Million
1,003,000 Added 43.14%
3,328,000 $117 Million
Q1 2024

May 15, 2024

BUY
$13.06 - $29.18 $30.4 Million - $67.8 Million
2,325,000 New
2,325,000 $66 Million
Q2 2023

Aug 14, 2023

SELL
$8.53 - $14.28 $4.27 Million - $7.14 Million
-500,000 Reduced 83.33%
100,000 $1.13 Million
Q1 2023

May 15, 2023

BUY
$10.88 - $15.0 $2.18 Million - $3 Million
200,000 Added 50.0%
600,000 $6.91 Million
Q4 2022

Feb 14, 2023

SELL
$9.37 - $13.8 $468,499 - $690,000
-50,000 Reduced 11.11%
400,000 $4.64 Million
Q3 2022

Nov 14, 2022

SELL
$7.2 - $15.17 $864,000 - $1.82 Million
-120,000 Reduced 21.05%
450,000 $5.72 Million
Q2 2022

Aug 15, 2022

SELL
$4.36 - $10.5 $784,800 - $1.89 Million
-180,000 Reduced 24.0%
570,000 $3.92 Million
Q1 2022

May 16, 2022

BUY
$6.52 - $12.27 $4.24 Million - $7.98 Million
650,000 Added 650.0%
750,000 $7.23 Million
Q4 2021

Feb 14, 2022

BUY
$11.89 - $16.07 $594,500 - $803,500
50,000 Added 100.0%
100,000 $1.19 Million
Q3 2021

Nov 15, 2021

SELL
$15.6 - $21.46 $780,000 - $1.07 Million
-50,000 Reduced 50.0%
50,000 $812,000
Q2 2021

Aug 16, 2021

BUY
$15.94 - $22.33 $1.59 Million - $2.23 Million
100,000 New
100,000 $2.1 Million

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.24B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.